Comparison Of Clinical Implications Of p16 Deletion In B-Lineage Acute Lymphoblastic Leukemia

This paper probes into the impact of P16 gene deletion on the prognosis of children and adults B-ALL.

With the adoption of the Flow Cytometry, G-banding Technique Karyotype Analysis and Fluorescence in situ hybridization (I-FISH) technology, this paper will retrospectively analyze the clinical data of the immunological and cytogenetic detection to the total 124 initial onset B-ALL patients, who were treated in our hospital from January 2006 to December 2008, including children (73 cases, median age 6 years old) and adults (51 cases, median age 29 years).

With the adoption of the I-FISH technology, the result data of the survey are exemplified as follows: in the group of 73 cases of child B-ALL patients, the incidence of P16 gene homozygous deletion, loss of heterozygosity and non-deletion are 13.7% (7 cases), 5.9% (3 cases), 80.4% (41 cases); in the group of 51 cases of adults, they are 13.7% (7 cases), 5.9% (3 cases), 80.4% (41 cases). In this data,recurrence rate in patients with p16 gene deletion is 43.5% (10 cases) in group of children, which is lower than that 90.0% (9 cases) in group of adults. The difference is statistically significant (P = 0.013 ). Overall Survival (OS) is compared in patients of children and adults with and without p16 gene deletion. The result shows that children aged from 1 to 14 with p16 gene deletion have lower Overall Survival (OS) than that without p16 gene deletion (P = 0.013). And it is the same in adult patients older than or are 15 years old (P = 0.020). The long-term disease-free survival DFS is no significant difference (P = 0.154) between that with and without p16 gene deletion in child group. On the contrary, the P16 gene deletion DFS is significantly lower than those without it in the adult group (P <0.001).

p16 gene deletion in B-ALL patients of children and adults is equally poor prognostic factors. Consequently, it is significant for the assessing prognosis and guiding clinical treatment by making a definite status of the p16 gene deletion.

No relevant conflicts of interest to declare.